【Abstract】Objective To investigate the effects of Roxadustat on iron metabolism in maintenance hemodialysis (MHD) patients with microinflammation state and renal anemia, in order to provide theoretic bases for the diagnosis and treatment of these patients. Methods A total of 68 MHD patients with microinflammation state and renal anemia admitted to Linyi Central Hospital from May to October, 2020 were enrolled in this study. They were equally divided into control group and study group by random number table method. The control group was treated with recombinant human erythropoietin (rhEPO) after hemodialysis, while the study group was treated with Roxadustat. They were treated for 3 months. Hemoglobin (Hb), serum iron (SI), total iron binding capacity (TIBC), transferrin saturation (TSAT), transferrin, serum ferritin (SF) and hepcidin were compared before and after 3 months of treatment between the two groups. Results There were no significant differences in age, gender, dialysis age, and the levels of Hb, SI, TIBC, TSAT, transferrin, SF, hepcidin, CRP and PTH between the two groups before treatment (P＞0.05). In the study group after the treatment, Hb, SI, transferrin, and TIBC increased significantly (for Hb, t=4.245, P<0.001 after 2 months, and t=6.433, P<0.001 after 3 months; for SI, t=2.984, P<0.001 after 2 months, and t=5.433, P<0.001 after 3 months;
for transferrin, t=3.254, P<0.001 after 2 months, and t=4.329, P<0.001 after 3 months; for TIBC, t=3.854, P< 0.001 after 2 months, and t=5.322, P<0.001 after 3 months), while SF, TSAT and hepcidin decreased significantly (for SF, t=2.245, P<0.030 after one month, t=3.851, P<0.001 after 2 months, and t=6.433, P<0.001 after 3 months; for TSAT, t=2.268, P<0.032 after one month, t=3.567, P<0.001 after 2 months, and t=4.852, P<0.001 after 3 months; for hepcidin, t=3.445, P<0.001 after 2 months, and t=7.343, P<0.001 after 3 months), as compared with those in the control group. Conclusion Compared with rhEPO, Roxadustat treatment can significantly correct abnormal iron metabolism, increase iron utilization, and improve renal anemia in MHD patients with microinflammation state and renal anemia. This study also provides theoretic bases for the diagnosis and treatment of these patients.
LIU Jia-Qiang
. The effect of Roxadustat on iron metabolism in hemodialysis patients with microinflammatory state[J]. Chinese Journal of Blood Purification, 2021
, 20(07)
: 465
-468
.
DOI: 10.3969/j.issn.1671-4091.2021.07.008
[1]. Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol. 2017; 18(1):345.
[2]. Yang C, Wang JW, Yang YZ, et al. Impact of anemia and chronic kidney disease on the risk of cardiovascular disease and all-cause mortality among diabetic patients. Beijing Da Xue Xue Bao Yi Xue Ban. 2018; 50(3):495-500.
[3]. Yamamoto T, Miyazaki M, Nakayama M, et al. Impact of hemoglobin levels on renal and non-renal clinical outcomes differs by chronic kidney disease stages: the Gonryo study. Clin Exp Nephrol. 2016; 20(4):595-602.
[4]. Zuo L, Wang M, Hou FF, et al. Anemia Management in the China Dialysis Outcomes and Practice Patterns Study. Blood Purif. 2016; 42(1): 33-43.
[5]. Li ZL, Tu Y, Liu BC. Treatment of Renal Anemia with Roxadustat: Advantages and Achievement. Kidney Dis (Basel). 2020; 6(2):65-73.
[6]. Sanghani NS, Haase VH. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience. Adv Chronic Kidney Dis. 2019; 26(4):253-266.
[7]. Dhillon S. Roxadustat: First Global Approval. Drugs. 2019; 79(5):563-572.
[8]. Chen N, Hao C, Liu BC, et al. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. N Engl J Med. 2019; 381(11):1011-1022.
[9]. 中国医师协会肾内科医师分会肾性贫血诊断和治疗共识专家组. 肾性贫血诊断与治疗中国专家共识(2018修订版). 中华肾脏病杂志. 2018, 34(11): 60-866.
[10]. 中华医学会肾脏病学分会. 重组人促红细胞生成素在肾性贫血中合理应用的专家共识. 中国血液净化. 2007, 6(8): 440-443.
[11]. Liu C, Li H. Correlation of the severity of chronic kidney disease with serum inflammation, osteoporosis and vitamin D deficiency. Exp Ther Med. 2019 Jan;17(1):368-372.
[12]. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019 Jan 3;133(1):40-50.
[13]. Wang CY, Babitt JL. Hepcidin regulation in the anemia of inflammation. Curr Opin Hematol. 2016 May;23(3):189-97.
[14]. Yilmaz M, Solak Y, Covic A, Goldsmith D, Kanbay M. Renal anemia of inflammation: the name is self-explanatory. Blood Purif. 2011;32(3):220-225.
[15]. 马晓莉, 孙雪峰, 曹雪莹, 等. 微炎症状态对维持性血液透析患者血清铁蛋白和转铁蛋白饱和度水平的影响. 中华肾病研究电子杂志. 2013, 2(1): 34-37.
[16]. Malyszko J, Malyszko JS, Matuszkiewicz-Rowinska J. Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease. Expert Opin Ther Targets. 2019 May;23(5):407-421.
[17]. Xu MM, Wang J, Xie JX. Regulation of iron metabolism by hypoxia-inducible factors. Sheng Li Xue Bao. 2017 Oct 25;69(5):598-610.
